Viemed Healthcare, Inc. (VMD) 股票分析

公司概述

Viemed Healthcare, Inc. operates primarily within the United States, delivering comprehensive home medical equipment (HME) and post-acute respiratory healthcare services to patients. The company focuses on providing respiratory disease management solutions, specifically targeting the treatment of chronic obstructive pulmonary disease (COPD) and other related conditions through its subsidiaries. As a key player in the Healthcare sector and the Medical Devices industry, Viemed addresses the growing demand for specialized care outside of traditional hospital settings. With a market capitalization of $378.31M and annual revenue of $270.28M, the firm demonstrates a significant operational footprint supported by a workforce of 1382 employees. These valuation and revenue figures indicate that Viemed has established a substantial presence in the specialized medical device and services market, positioning it as a mid-cap entity with meaningful scale in its specific niche.

财务健康

Viemed Healthcare reported a trailing twelve-month revenue of $270.28M, generating a net income of $14.93M and an EBITDA of $50.45M during the same period. The substantial gap between the $270.28M revenue and the $14.93M net income reveals a cost structure where approximately 94.5% of revenue is consumed by operating expenses, taxes, and other deductions before arriving at the bottom line. The company generated free cash flow of $15.72M, which indicates positive liquidity generation and provides the financial flexibility to fund operations or pursue strategic initiatives without immediate reliance on external financing. Profitability is reflected across three distinct margin levels: a gross margin of 57.5%, an operating margin of 11.5%, and a profit margin of 5.5%. The 57.5% gross margin suggests strong pricing power or high-value service delivery relative to the cost of goods sold, while the narrower operating and profit margins highlight the significant overhead costs inherent in providing HME and respiratory services. Regarding the balance sheet, Viemed holds $13.50M in cash against $15.95M in debt, resulting in a debt-to-equity ratio of 11.11% and a current ratio of 1.18. The current ratio of 1.18 indicates that the company possesses sufficient current assets to cover its short-term liabilities, though it operates with limited liquidity buffer above the 1.0 threshold. Return on equity stands at 11.1%, while return on assets is 7.3%, metrics that collectively reveal management's effectiveness in utilizing shareholder capital and total assets to generate profit.

估值评估

The stock trades at a P/E ratio of 26.49 on a trailing twelve-month basis, with a forward P/E of 24.50, implying that the market expects earnings growth to accelerate in the coming year to justify the lower forward multiple. The price-to-book ratio is 2.63, indicating that the market values the company at a premium of roughly 163% over its net asset book value, which is typical for firms with significant intangible assets or growth potential. Alternative valuation metrics further contextualize the equity price, with a price-to-sales ratio of 1.40 and an EV/EBITDA of 7.59, suggesting the company is valued at less than one times its enterprise earnings before interest, taxes, depreciation, and amortization. Over the last year, the stock price has ranged between a 52-week low of $5.93 and a 52-week high of $10.06, providing a clear historical trading band for benchmarking current levels. The beta of 1.16 indicates that the stock price exhibits higher volatility than the broader market, moving 16% more than the benchmark index on average during periods of market fluctuation.

Growth & Income

Viemed Healthcare has demonstrated robust expansion with revenue growth of 25.5% year-over-year and earnings growth of 29.8% year-over-year. The earnings growth rate of 29.8% exceeds the revenue growth rate of 25.5%, implying that the company is improving its operational efficiency and profitability as it scales its business. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning it retains all of its net income to reinvest into growth initiatives rather than distributing cash to shareholders. This strategy of retaining earnings supports the high growth trajectory observed in both revenue and profitability, prioritizing capital allocation for expansion over current income distribution. The overall growth and income profile for Viemed is characterized by aggressive top-line expansion and margin improvement rather than passive income generation through dividends.